| Literature DB >> 33841875 |
Nahid Tabibzadeh1,2, Maxime Zalc3,4, Thibault Michel3,4, Emmanuel Letavernier5,6, Alexandre Mebazaa3,4, Antoine Borouchaki3,4, Vincent Frochot5,6, Michel Daudon5,6, Jean-Philippe Haymann5,6, Benjamin G Chousterman3,4.
Abstract
Entities:
Year: 2020 PMID: 33841875 PMCID: PMC8023188 DOI: 10.1093/ckj/sfaa187
Source DB: PubMed Journal: Clin Kidney J ISSN: 2048-8505
Main characteristics of patients and urinary crystals
| Characteristics | |
|---|---|
| Age, years | 57 (45–69) |
| Female, | 42 (41) |
| Admission diagnosis, | |
| Sepsis/infection | 35 (34) |
| Brain injury | 44 (43) |
| Haemorrhagic shock | 2 (2) |
| Polytraumatism | 1 (1) |
| Major abdominal surgery | 8 (8) |
| Other causes | 12 (12) |
| Charlson comorbidity index | 4 (2–5) |
| Diabetes mellitus, | 18 (17.5) |
| Chronic kidney disease, | 7 (7) |
| SAPS II | 37 (21–52) |
| In-hospital mortality, | 22 (21) |
| Length of hospital stay, days | 23 (14–36) |
| Serum creatinine at ICU admission, µmol/L | 71 (59–100) |
| Serum creatinine at discharge, µmol/L | 63.5 (51–93) |
| Maximal serum creatinine during hospital stay, µmol/L | 92.5 (67–166) |
| Delay between admission and crystalluria study, days | 1 (1–3) |
| Ongoing infection at the time of crystalluria study, | 42 (41) |
| AKI, | 40 (39) |
| Positive crystalluria, | 53 (51) |
| Type of crystals, | |
| Uric acid | 27 (51) |
| Calcium oxalate | 12 (23) |
| Amoxicilline | 1 (2) |
| Vancomycine | 1 (2) |
| Other (struvite, brushite, ACP) | 12 (21) |
Values are median (interquartile range) and number (percentage).
SAPS II, simplified acute physiology score II; ICU, intensive care unit; ACP, amorphous calcium phosphate.
Characteristics of patients according to the presence of urine crystals and according to the presence of uric acid crystals
| Variable | No urine crystals | Urine crystals | P-value | No UA crystals | UA crystals | P-value |
|---|---|---|---|---|---|---|
| ( | ( | ( | ( | |||
| Age, years | 57 (40–70) | 57 (49–66) | 0.30 | 56 (42–66) | 61 (51–74) | 0.07 |
| Female sex, | 25 (50) | 17 (32) | 0.07 | 36 (47) | 7 (26) | 0.09 |
| Admission diagnosis | ||||||
| Neurological | 28 (56) | 16 (30) | 36 (47) | 8 (30) | ||
| Infection | 13 (26) | 22 (41) | 20 (26) | 15 (55) | ||
| Others | 9 (18) | 15 (28) | 20 (26) | 4 (15) | ||
| SAPS II | 42 (25–54) | 32 (20–46) | 0.11 | 36 (19–52) | 41 (25–50) | 0.39 |
| Diabetes, | 6 (12) | 12 (23) | 0.15 | 12 (16) | 6 (22) | 0.62 |
| AKI, | 14 (28) | 24 (45) | 0.07 | 21 (28) | 17 (63) | |
| Infection/sepsis, | 14 (28) | 28 (53) | 20 (26) | 22 (81) | ||
| CKD, | 4 (8) | 3 (6) | 0.94 | 4 (5) | 3 (11) | 0.55 |
| Uricaemia, µmol/L | 232 (170–360) | 298 (144–441) | 0.67 | 216 (152–357) | 425 (230–458) | |
| Leukocytes, 109/L | 13 (10–17) | 13.3 (6.6–21.5) | 0.13 | 12.5 (9.7–16.6) | 11.1 (8.9–18.4) | 0.61 |
| Blood pH | 7.39 (7.36–7.45) | 7.40 (7.35–7.44) | 0.87 | 7.41 (7.36–7.45) | 7.40 (7.32–7.42) | 0.13 |
| Serum HCO3−, mmol/L | 22 (20–24) | 23 (20–25) | 0.33 | 22 (20–25) | 23 (20–25) | 0.72 |
| BUN, mmol/L | 5.4 (3.3–7.9) | 7.3 (4.9–10.4) | 5.6 (3.5–7.9) | 8.8 (6.1–11.5) | ||
| SCreat, µmol/L | 69 (50–93) | 82 (61–124) | 0.17 | 67 (50–94) | 96 (70–145) | |
| SCreat-admission, µmol/L | 68 (55–88) | 78 (62–108) | 0.12 | 68 (57–86) | 98 (68–120) | |
| Na-U, mmol/L | 61 (32–112) | 59 (31–106) | 0.87 | 73 (33–120) | 39 (22–68) | |
| K-U, mmol/L | 40 (28–55) | 35 (24–49) | 0.33 | 39 (25–53) | 37 (30–50) | 0.87 |
| Creat-U, mmol/L | 7.7 (5.5–12.4) | 7.9 (4.9–12.3) | 0.99 | 7.7 (5.5–11.3) | 11.5 (5.1–15.6) | 0.13 |
| PO4-U, mmol/L | 19.3 (7.6–34.2) | 21.2 (12.8–32.7) | 0.26 | 17.9 (8.8–29.3) | 31.8 (18.0–41.2) | |
| Uric acid-U, mmol/L | 2.7 (1.3–3.7) | 2.8 (1.7–4.4) | 0.27 | 2.7 (1.3–3.7) | 3.0 (2.5–6.3) | |
| FeAU, % | 11.5 (8.2–17.2) | 13.4 (6.6–21.5) | 0.77 | 12.1 (8.4–17.4) | 10.7 (5.5–23.1) | 0.83 |
| Urea-U, mmol/L | 201 (113–264) | 239 (127–314) | 0.10 | 198 (107–266) | 258 (172–367) | |
| Prot-U, mg/mL | 22 (8–35) | 21 (10–65) | 0.22 | 22 (8–38) | 23 (14–76) | 0.05 |
| sCa-U, mmol/L | 87 (24–164) | 93 (24–289) | 0.43 | 106 (35–273) | 40 (15–117) | |
| Mg-U, mmol/L | 2.5 (1.0–4.9) | 2.4 (1.1–4.9) | 0.99 | 2.3 (1.1–5.0) | 3.2 (0.8–4.9) | 0.96 |
| Citrate-U, mmol/L | 1.00 (0.18–2.40) | 0.92 (0.15–1.69) | 0.55 | 1.02 (0.24–2.30) | 0.42 (0.07–1.45) | |
| Osmolality-U, mOsm/kgH2O | 586 (421–761) | 573 (429–761) | 0.85 | 565 (408–759) | 599 (466–189) | 0.37 |
| Urine pH | 5.9 (5.3–6.0) | 5.9 (5.3–6.6) | 0.14 | 5.9 (5.3–6.5) | 5.6 (5.3–5.9) | |
| LOS, days | 20 (12–36) | 24 (15–39) | 0.38 | 20 (12–42) | 26 (17–34) | 0.29 |
| SCreat-discharge, µmol/L | 60 (49–90) | 70 (52–105) | 0.22 | 60 (50–82) | 88 (55–135) | |
| Maximal SCreat, µmol/L | 86 (66–150) | 105 (70–175) | 0.18 | 84 (65–147) | 131 (94–199) | |
| In-hospital mortality, | 10 (20) | 11 (21) | 1 | 14 (18) | 7 (26) | 0.58 |
Values are median (interquartile range) and number (percentage). SAPS II, simplified acute physiology score II; UA, uric acid; CKD, chronic kidney disease; BUN, blood urea nitrogen; SCreat, serum creatinine concentration; FeAU, fractional excretion of uric acid; U, urinary; LOS, length of hospital stay. P-values in bold and with asterisk are considered significant (<0.05).